MA44060B1 - Protéines de liaison à un antigène anti-tl1a et leurs utilisations - Google Patents

Protéines de liaison à un antigène anti-tl1a et leurs utilisations

Info

Publication number
MA44060B1
MA44060B1 MA44060A MA44060A MA44060B1 MA 44060 B1 MA44060 B1 MA 44060B1 MA 44060 A MA44060 A MA 44060A MA 44060 A MA44060 A MA 44060A MA 44060 B1 MA44060 B1 MA 44060B1
Authority
MA
Morocco
Prior art keywords
binding proteins
tl1a
antigen binding
antigen
tnf
Prior art date
Application number
MA44060A
Other languages
English (en)
Other versions
MA44060A (fr
Inventor
Gunasekaran Kannan
Hailing Hsu
Michelle Hortter
Edward J. Belouski
Kenneth W. Walker
Original Assignee
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2016/052006 external-priority patent/WO2017049004A1/fr
Application filed by Amgen Inc. filed Critical Amgen Inc.
Publication of MA44060A publication Critical patent/MA44060A/fr
Publication of MA44060B1 publication Critical patent/MA44060B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Ecology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne des protéines de liaison à un antigène qui se lient à TL1A, comprenant des protéines de liaison à un antigène bispécifiques (par exemple des anticorps) contre TL1A et TNF-α. Ces anticorps bispécifiques peuvent être dans un format d'immunoglobuline tétramère, une paire chaîne lourde-chaîne légère de l'anticorps étant dirigée contre TL1A et l'autre contre le TNF-α. Les protéines de liaison à un antigène bispécifiques peuvent également être incluses dans une fusion IgG-scFv, un anticorps tétramère classique dirigé contre un antigène étant fusionné à une paire d'unités Fv à chaîne unique dirigée contre l'autre. La protéine de liaison à l'antigène bispécifique peut également être incluse dans une fusion IgG-Fab, une molécule Fab qui se lie à un antigène étant fusionnée à chaque chaîne lourde d'un anticorps tétramère classique dirigé contre l'autre antigène. L'invention concerne également des utilisations des protéines de liaison anti-TL1A et des protéines de liaison à un antigène anti-TL1A/anti-TNF-alpha, et leurs formulations pharmaceutiques.
MA44060A 2015-12-16 2016-12-14 Protéines de liaison à un antigène anti-tl1a et leurs utilisations MA44060B1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562268432P 2015-12-16 2015-12-16
US201662333063P 2016-05-06 2016-05-06
PCT/US2016/052006 WO2017049004A1 (fr) 2015-09-15 2016-09-15 Protéines de liaison à l'antigène tétraspécifiques et bispécifiques tétravalentes et utilisations de celles-ci
PCT/US2016/066722 WO2017106383A1 (fr) 2015-12-16 2016-12-14 Protéines de liaison à un antigène bispécifiques anti-tl1a/anti-tnf-alpha et leurs utilisations
EP16822583.7A EP3390444B1 (fr) 2015-12-16 2016-12-14 Protéines de liaison à un antigène anti-tl1a et leurs utilisations

Publications (2)

Publication Number Publication Date
MA44060A MA44060A (fr) 2018-10-24
MA44060B1 true MA44060B1 (fr) 2026-03-31

Family

ID=59057540

Family Applications (1)

Application Number Title Priority Date Filing Date
MA44060A MA44060B1 (fr) 2015-12-16 2016-12-14 Protéines de liaison à un antigène anti-tl1a et leurs utilisations

Country Status (34)

Country Link
US (2) US11104745B2 (fr)
EP (2) EP4640705A3 (fr)
JP (1) JP7263007B2 (fr)
KR (1) KR20180099723A (fr)
CN (1) CN109311971B (fr)
AU (2) AU2016370659B2 (fr)
BR (1) BR112018012096A2 (fr)
CA (1) CA3008267A1 (fr)
CL (3) CL2018001596A1 (fr)
CO (1) CO2018007355A2 (fr)
CR (1) CR20180365A (fr)
DK (1) DK3390444T3 (fr)
EA (1) EA201891322A1 (fr)
ES (1) ES3064312T3 (fr)
FI (1) FI3390444T3 (fr)
HR (1) HRP20260195T1 (fr)
IL (2) IL314885A (fr)
JO (1) JO3816B1 (fr)
LT (1) LT3390444T (fr)
MA (1) MA44060B1 (fr)
MX (1) MX2018007424A (fr)
MY (1) MY205021A (fr)
PH (1) PH12018501284A1 (fr)
PT (1) PT3390444T (fr)
RS (1) RS67851B1 (fr)
SG (2) SG11201804857WA (fr)
SI (1) SI3390444T1 (fr)
SM (1) SMT202600071T1 (fr)
TN (1) TN2019000275A1 (fr)
TW (1) TWI799368B (fr)
UA (2) UA124305C2 (fr)
UY (1) UY37027A (fr)
WO (1) WO2017106383A1 (fr)
ZA (2) ZA201904491B (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010062960A2 (fr) 2008-11-26 2010-06-03 Cedars-Sinai Medical Center Méthodes de détermination d'une réceptivité à une thérapie par anti-tnfα lors d’une maladie intestinale inflammatoire
MX2014003689A (es) 2011-09-30 2014-12-05 Teva Pharmaceuticals Australia Pty Ltd Anticuerpos contra tl1a y sus usos.
UY35148A (es) * 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
KR20230109779A (ko) 2013-03-27 2023-07-20 세다르스-신나이 메디칼 센터 Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한섬유증 및 염증의 완화 및 반전
CN105358713B (zh) 2013-05-17 2020-02-28 雪松-西奈医学中心 与克罗恩病相关的tnfsf15和dcr3的变体
EP4105236A1 (fr) 2013-07-19 2022-12-21 Cedars-Sinai Medical Center Anticorps contre tl1a (tnfsf15) pour le traitement des maladies inflammatoires de l'intestin
TWI703158B (zh) 2015-09-18 2020-09-01 美商希佛隆公司 特異性結合tl1a之抗體
CR20180365A (es) 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
GB201522394D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
KR20180127416A (ko) 2016-03-17 2018-11-28 세다르스-신나이 메디칼 센터 Rnaset2를 통한 염증성 장 질환의 진단 방법
CN118240830A (zh) 2016-10-26 2024-06-25 西达-赛奈医疗中心 中和抗tl1a单克隆抗体
US12384850B2 (en) 2017-06-25 2025-08-12 Systimmune, Inc. Guidance and navigation control proteins and method of making and using thereof
EP4424707A3 (fr) * 2017-09-19 2024-11-13 Tillotts Pharma AG Variantes d'anticorps
EP3735270A1 (fr) 2018-01-05 2020-11-11 Modernatx, Inc. Polynucléotides codant pour des anticorps anti-virus du chikungunya
CN112585165B8 (zh) 2018-04-25 2025-02-14 普罗米修斯生物科学公司 优化的抗tl1a抗体
CN111909268B (zh) * 2019-05-07 2022-04-19 北京天成新脉生物技术有限公司 低免疫原性低ADCC/CDC功能抗TNF-α人源化单克隆抗体TCX060及其应用
CN114375339A (zh) * 2019-05-14 2022-04-19 普罗米修斯生物科学公司 Tl1a患者选择方法、系统和装置
SG11202112926YA (en) 2019-05-30 2021-12-30 Amgen Inc Engineering the hinge region to drive antibody dimerization
AU2019456113A1 (en) * 2019-07-11 2022-03-03 Wuhan Yzy Biopharma Co., Ltd. Tetravalent symmetric bispecific antibody
PH12022550141A1 (en) 2019-07-19 2023-12-04 Oncoresponse Inc Immunomodulatory antibodies and methods of use thereof
AU2020342512A1 (en) * 2019-09-03 2022-03-31 Amgen Inc. IL-22 oral, intra-rectal, or other gut-related compositions and methods of use thereof
CN114901311A (zh) 2019-10-24 2022-08-12 普罗米修斯生物科学公司 Tnf样配体1a（tl1a）的人源化抗体及其用途
CN113121696A (zh) * 2019-12-31 2021-07-16 周易 Fab改造诱导形成的双特异性抗体及其制备方法和用途
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
US20230159649A1 (en) * 2020-04-02 2023-05-25 La Jolla Institute For Immunology Methods and combinations for dual targeting of tnf family members
EP4153625A4 (fr) * 2020-05-20 2024-09-25 The Trustees Of Columbia University In The City Of New York Anticorps neutralisants puissants contre le sras-cov-2, leur génération et leurs utilisations
WO2022010912A1 (fr) 2020-07-06 2022-01-13 Flagship Pioneering Innovations Vi, Llc Molécules de liaison à l'antigène ciblant le sars-cov-2
JP2023534923A (ja) 2020-07-06 2023-08-15 フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー ＳＡＲＳ－ＣｏＶ－２を標的にする抗原結合分子
WO2022020680A1 (fr) 2020-07-23 2022-01-27 Othair Prothena Limited Anticorps anti-abêta
JP2023538897A (ja) * 2020-08-20 2023-09-12 アムジエン・インコーポレーテツド Ｆａｂ領域中に非標準的なジスルフィドを有する抗原結合タンパク質
AU2021332340A1 (en) 2020-08-26 2023-10-05 Flagship Pioneering Innovations Vi, Llc Antigen binding molecules targeting sars-cov-2
JP2023551602A (ja) * 2020-11-13 2023-12-08 プロメテウス バイオサイエンシーズ，インク． Ｔｌ１ａを標的とする炎症性疾患の治療のための方法、システム、およびキット
EP4326772A4 (fr) * 2021-04-23 2025-03-05 Chimagen Biosciences, Ltd. Anticorps hétérodimères et fragment de liaison à l'antigène de ceux-ci
IL325993A (en) 2023-08-11 2026-03-01 Paragon Therapeutics Inc TL1A binding proteins and methods of use
US20250230251A1 (en) 2023-12-20 2025-07-17 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rb) and related methods
TW202542181A (zh) * 2023-12-26 2025-11-01 俄羅斯聯邦商拜奧卡德聯合股份公司 特異性結合類ｔｎｆ配體１ａ（ｔｌ１ａ）之單株抗體或其抗原結合片段及其用途
WO2026019692A2 (fr) * 2024-07-15 2026-01-22 Flagship Pioneering Innovations Vii, Llc Protéines de fusion immunomodulatrices et procédés associés
WO2026035986A1 (fr) 2024-08-07 2026-02-12 Bighat Biosciences, Inc. Anticorps anti-cdh17 humanisés et leur utilisation

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603044A (en) 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
JP3202999B2 (ja) 1991-01-31 2001-08-27 協和醗酵工業株式会社 肝移行性リポソーム製剤
US5830877A (en) 1993-08-26 1998-11-03 The Regents Of The University Of California Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory
US7820798B2 (en) 1994-11-07 2010-10-26 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
ATE279947T1 (de) 1996-03-18 2004-11-15 Univ Texas Immunglobulinähnliche domäne mit erhöhten halbwertszeiten
ATE549918T1 (de) 1996-12-03 2012-04-15 Amgen Fremont Inc Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden
US6218371B1 (en) 1998-04-03 2001-04-17 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
EP2168984B1 (fr) 1999-03-25 2012-08-29 Abbott GmbH & Co. KG Anticorps humains qui se lient au IL-12 humain et procédé de fabrication
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
WO2001011050A1 (fr) 1999-08-04 2001-02-15 Amgen Inc. Fhm, NOUVEAU MEMBRE DE LA FAMILLE DES SUPERGENES LIGANDS DU TNF__
ATE472556T1 (de) 2002-12-02 2010-07-15 Amgen Fremont Inc Gegen den tumor nekrose faktor gerichtete antikörper und deren verwendungen
CA2536086C (fr) 2003-08-20 2013-03-19 University Of Miami Inhibition du dr3 dans le traitement de l'inflammation pulmonaire allergique
CN101198698B (zh) 2005-03-31 2014-03-19 中外制药株式会社 通过调节多肽缔合制备多肽的方法
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US20110217310A1 (en) 2007-01-10 2011-09-08 Siegel Richard M Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology
MX2010005282A (es) 2007-11-13 2010-08-31 Teva Pharma Anticuerpos humanizados contra tl1a.
EP3663318A1 (fr) 2008-01-07 2020-06-10 Amgen Inc. Procédé de fabrication de molécules hétérodimères fc d'anticorps utilisant les effets de conduite électrostatique
ES2828627T3 (es) 2008-04-25 2021-05-27 Kyowa Kirin Co Ltd Anticuerpo multivalente estable
AU2010233993A1 (en) 2009-04-07 2011-09-08 Roche Glycart Ag Bispecific anti-ErbB-1/anti-c-Met antibodies
US8703132B2 (en) 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
JO3375B1 (ar) * 2010-11-08 2019-03-13 Regeneron Pharma أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a)
UY33827A (es) 2010-12-22 2012-07-31 Abbott Lab Proteínas de unión a media-inmunoglobulina y sus usos
WO2012088290A2 (fr) 2010-12-22 2012-06-28 Abbott Laboratories Protéines de liaison à trois domaines variables et leurs utilisations
AU2012259312A1 (en) 2011-05-20 2013-12-12 Government Of The United States, As Represented By The Secretary Department Of Health And Human Services Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology and antibodies thereof
WO2013041687A1 (fr) 2011-09-23 2013-03-28 Amgen Research (Munich) Gmbh Molécules de liaison bispécifiques pour 5t4 et cd3
MX2014003689A (es) 2011-09-30 2014-12-05 Teva Pharmaceuticals Australia Pty Ltd Anticuerpos contra tl1a y sus usos.
ES2711554T3 (es) 2012-05-22 2019-05-06 Bristol Myers Squibb Co Anticuerpos biespecíficos contra IL-17A/F IL-23 y sus usos
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
MX385344B (es) 2012-11-28 2025-03-18 Zymeworks Bc Inc Pares de cadena pesada-cadena ligera de inmunoglobulina modificados genéticamente y usos de estos.
EA201591153A1 (ru) 2013-01-02 2016-01-29 Гленмарк Фармасьютикалс С.А. Антитела, связывающиеся с tl1a, и их применение
TW201444867A (zh) 2013-03-08 2014-12-01 Lilly Co Eli 抗ｔｎｆ－抗ｉｌ－１７雙特異性抗體
PH12022550138A1 (en) 2013-03-13 2023-03-06 Amgen Inc Proteins specific for baff and b7rp1 and uses thereof
US9546203B2 (en) 2013-03-14 2017-01-17 Amgen Inc. Aglycosylated Fc-containing polypeptides with cysteine substitutions
MX2015013163A (es) 2013-03-15 2016-04-04 Zyngenia Inc Complejos multiespecificos multivalente y monovalentes y sus usos.
WO2014144357A1 (fr) 2013-03-15 2014-09-18 Merck Patent Gmbh Anticorps bispécifiques tétravalents
UA118028C2 (uk) * 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
EP3068801A1 (fr) 2013-11-13 2016-09-21 Pfizer Inc. Anticorps spécifiques du ligand 1a de type facteur de nécrose tumorale et compositions ainsi qu'utilisations associées
US20160052006A1 (en) 2013-11-22 2016-02-25 Sheila S. Pirtle Spray Bottle
TWI703158B (zh) 2015-09-18 2020-09-01 美商希佛隆公司 特異性結合tl1a之抗體
CR20180365A (es) 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS

Also Published As

Publication number Publication date
JO3816B1 (ar) 2021-01-31
SMT202600071T1 (it) 2026-03-09
IL259847A (en) 2018-07-31
MX2018007424A (es) 2018-09-21
US20220213226A1 (en) 2022-07-07
CN109311971B (zh) 2024-09-24
UA130718C2 (uk) 2026-04-29
LT3390444T (lt) 2026-02-25
JP7263007B2 (ja) 2023-04-24
US11104745B2 (en) 2021-08-31
TWI799368B (zh) 2023-04-21
AU2016370659A1 (en) 2018-06-28
MA44060A (fr) 2018-10-24
CN109311971A (zh) 2019-02-05
RS67851B1 (sr) 2026-03-31
CA3008267A1 (fr) 2017-06-22
SG10201912002YA (en) 2020-02-27
PH12018501284A1 (en) 2019-01-28
BR112018012096A2 (pt) 2018-11-27
MY205021A (en) 2024-09-27
SG11201804857WA (en) 2018-07-30
PT3390444T (pt) 2026-02-25
CL2018001596A1 (es) 2018-09-28
UY37027A (es) 2017-06-30
UA124305C2 (uk) 2021-08-25
ZA201904491B (en) 2020-03-25
NZ743379A (en) 2025-07-25
EP3390444A1 (fr) 2018-10-24
WO2017106383A1 (fr) 2017-06-22
SI3390444T1 (sl) 2026-04-30
WO2017106383A4 (fr) 2017-09-08
CO2018007355A2 (es) 2018-07-19
US20190119407A1 (en) 2019-04-25
ES3064312T3 (en) 2026-04-23
TN2019000275A1 (en) 2021-05-07
EP3390444B1 (fr) 2025-11-19
IL314885A (en) 2024-10-01
NZ783153A (en) 2025-07-25
CL2021001179A1 (es) 2021-11-19
EP4640705A3 (fr) 2026-03-04
AU2024200534A1 (en) 2024-04-11
TW201731871A (zh) 2017-09-16
CR20180365A (es) 2018-09-28
KR20180099723A (ko) 2018-09-05
AU2016370659B2 (en) 2024-02-15
HRP20260195T1 (hr) 2026-03-27
EP4640705A2 (fr) 2025-10-29
EA201891322A1 (ru) 2019-01-31
ZA202003133B (en) 2025-06-25
CL2023002597A1 (es) 2024-03-15
DK3390444T3 (da) 2026-02-23
FI3390444T3 (fi) 2026-02-11
JP2019502692A (ja) 2019-01-31
US12552877B2 (en) 2026-02-17

Similar Documents

Publication Publication Date Title
PH12018501284A1 (en) Anti-tl1a/anti-tnf-alpha bispecific antigen binding proteins and uses thereof
PH12021500051A1 (en) Cd3 antigen binding fragments and compositions comprising same
CR20170383A (es) Anticuerpos anti-cd3, anticuerpos anti-cd-123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
PH12018500635A1 (en) Bispecific antibodies specific for pd1 and tim3
WO2018057735A8 (fr) Anticorps pour siglec-15 et leurs méthodes d'utilisation
WO2013136186A3 (fr) Anticorps bispécifiques aisément isolés avec un format d'immunoglobuline native
AU2014232501C1 (en) Heterodimeric proteins
WO2015184001A8 (fr) Glycoanticorps anti-thf-alpha et leurs utilisations
EA201591153A1 (ru) Антитела, связывающиеся с tl1a, и их применение
CL2011003148A1 (es) Proteina biespecifica de union a antigeno, que comprende a)2 cadenas ligeras y 2 cadenas pesadas de un anticuerpo que se une especificamente a un antigeno y 2 fragmentos fab, b)dos fragmentos fab adicionales de un anticuerpo que se une especificamente a un segundo antigeno; metodo de preparacion; composicion farmaceutica y uso.
IN2014MN00873A (fr)
MX2013011176A (es) Proteinas de union de tipo anticuerpo con region variable dual que tienen orientacion de la region de union con entrecruzamiento.
WO2015006337A3 (fr) Compositions et procédés permettant d'augmenter la demi-vie d'une protéine dans un sérum
EA201990673A1 (ru) Антитела, специфически связывающиеся с il-17a, и их функциональные фрагменты
MX2018005831A (es) Gradientes de ph-sal opuestos para separaciones de proteina mejoradas.
EA201990895A1 (ru) Антитела к о1 и варианты их применения
BR112014019773A8 (pt) Ligantes para anticorpo e proteína de fusão fc para cromatografia de afinidade
ZA202104990B (en) Monoclonal antibody or antigen binding fragment thereof that binds to the l protein of the human parainfluenza virus (piv); method and kit for detecting piv
EP4495142A3 (fr) Construction bispécifique de liaison à un antigène
PH12015501650A1 (en) Human antibody specific to human metapneumovirus, or antigen-binding fragment thereof
ECSP21028958A (es) Anticuerpo monoclonal que se une específicamente al antígeno cd20
MX2019002455A (es) Metodos para la identificacion de epitopes.
MX2019003908A (es) Metodo por multiproteasa.
TN2018000212A1 (en) Anti-tl1a/anti-tnf-alpha bispecific antigen binding proteins and uses thereof
MX2022003191A (es) Terapias de combinacion con anticuerpos entpd2 y cd73.